Remdesivir for the Treatment of Covid-19 — Final Report

Abstract

Our data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. (Funded by the National Institute of Allergy and Infectious Diseases and others; ACTT-1 ClinicalTrials.gov number, NCT04280705.).

Keywords

Coronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyMedicineInternal medicineOutbreak

MeSH Terms

Adenosine MonophosphateAdministrationIntravenousAdultAgedAlanineAntiviral AgentsBetacoronavirusCOVID-19Coronavirus InfectionsDouble-Blind MethodExtracorporeal Membrane OxygenationFemaleHumansKaplan-Meier EstimateMaleMiddle AgedOxygen Inhalation TherapyPandemicsPneumoniaViralRespirationArtificialSARS-CoV-2Time FactorsYoung AdultCOVID-19 Drug Treatment

Affiliated Institutions

Related Publications

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

Evan J. Anderson , Nadine Rouphael , Alicia T. Widge +34 more

In this small study involving older adults, adverse events associated with the mRNA-1273 vaccine were mainly mild or moderate. The 100-μg dose induced higher binding- and neutra...

2020 New England Journal of Medicine 1581 citations

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Lisa A. Jackson , Evan J. Anderson , Nadine Rouphael +30 more

The mRNA-1273 vaccine induced anti-SARS-CoV-2 immune responses in all participants, and no trial-limiting safety concerns were identified. These findings support further develop...

2020 New England Journal of Medicine 3382 citations

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Edward E. Walsh , Robert W. Frenck , Ann R. Falsey +22 more

The safety and immunogenicity data from this U.S. phase 1 trial of two vaccine candidates in younger and older adults, added to earlier interim safety and immunogenicity data re...

2020 New England Journal of Medicine 2665 citations

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Fernando P. Polack , Stephen J. Thomas , Nicholas Kitchin +26 more

A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral...

2020 New England Journal of Medicine 14917 citations

The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application

Stephen A. Lauer , Kyra H. Grantz , Qifang Bi +6 more

U.S. Centers for Disease Control and Prevention, National Institute of Allergy and Infectious Diseases, National Institute of General Medical Sciences, and Alexander von Humbold...

2020 Annals of Internal Medicine 6498 citations

Publication Info

Year: 2020
Type: article
Volume: 383
Issue: 19
Pages: 1813-1826
Citations: 7559
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

Remdesivir for the Treatment of Covid-19 — Final Report

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

7559

OpenAlex

242

Influential

5908

CrossRef

Cite This

APA Style

                            
                                
                                    John H. Beigel, 
                                
                                    Kay M Tomashek, 
                                
                                    Lori E. Dodd
                                
                                et al.
                            
                            (2020). 
                            Remdesivir for the Treatment of Covid-19 — Final Report. 
                            New England Journal of Medicine
                            , 383
                            (19)
                            , 1813-1826.
                            https://doi.org/10.1056/nejmoa2007764
                        

Identifiers

DOI: 10.1056/nejmoa2007764
PMID: 32445440
PMCID: PMC7262788

Data Quality

Data completeness: 90%